search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


CB1 receptor availability and its relation to cannabis use in psychosis


- candidate number3948
- NTR NumberNTR1439
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR9-sep-2008
- Secondary IDs2008-02 
- Public TitleCB1 receptor availability and its relation to cannabis use in psychosis
- Scientific TitleInvestigating CB1 receptor availability and its relation to cannabis use in psychosis: A [18F] MK9470 Positron Emission Tomography study
- ACRONYMN/A
- hypothesisCannabis users with and without psychotic illness differ in CB1 receptor availability in striatal and extrastriatal regions as measured with PET and [18F] MK9470
- Healt Condition(s) or Problem(s) studiedPsychosis, Cannabis
- Inclusion criteria1. Age 18-50 years
2. Life-time use of cannabis without having experienced negative effects
3. Being capable to consent and having signed informed consent
4. BMI between 18.5 and 27
5. Clinical diagnosis of non-affective psychosis according to DSM-IV (applies only to patients)
- Exclusion criteria1. Head trauma with loss of consciousness of more than 1 hour
2. Respiratory, cardiovasculatory, neurological disease, severe renal or liver dysfunction
3. Alcohol use in excess of 5 units per day
4. Weekly use of illicit drugs other than cannabis
5. Current use of antipsychotic medication or medication known to interfere with the CB1 receptor
6. Pregnancy and breast-feeding
7. Personal or family history of psychosis (applies only to controls)
- mec approval receivedno
- multicenter trialyes
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeintervention
- planned startdate 1-nov-2008
- planned closingdate31-okt-2010
- Target number of participants30
- InterventionsPET and [18F]MK9470, a CB1 receptor ligand as a measure of CB1 receptor availability in vivo.
- Primary outcome- Striatal and extrastriatal [18F]MK9470 binding.
- Secondary outcome- Differences in striatal and extrastriatal [18F]MK9470 binding as a function of genotypic variation of functional polymorphisms like the COMT Val158Met polymorphism
- TimepointsOne timepoint (t0)
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESDr. Cecile Henquet
- CONTACT for SCIENTIFIC QUERIESDr. Cecile Henquet
- Sponsor/Initiator University Maastricht (UM), UZ Gasthuisberg , Katholieke Universiteit Leuven
- Funding
(Source(s) of Monetary or Material Support)
NWO
- PublicationsN/A
- Brief summaryThe study aims at contributing to the investigation of the biological mechanism behind the cannabis-psychosis relationship. In order to be able to prevent and to better treat psychotic illness, it is of crucial importance to understand the biological pathway through which THC may be causally related to psychosis, and to identify factors that may moderate this pathway. The distribution of CB1 receptors in dopamine-rich regions, such as the striatum, and dopaminergic projection areas, such as the prefrontal cortex, constitutes a prime candidate. By using PET and [18F]MK9470, striatal and extrastriatal CB1 receptor availability is measured in cannabis users with and without psychotic illness.
- Main changes (audit trail)
- RECORD9-sep-2008 - 16-sep-2008


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl